Impact of Socioeconomic Characteristics and Comorbidities on Therapy Initiation and Outcomes of Newly Diagnosed Multiple Myeloma: Real-World Data From a Resource-Constrained Setting

Vargas-Serafin, Cesar; Acosta‐Medina, Aldo A.; Ordoñez-González, Irvin; Martínez-Baños, Déborah; Bourlon, Christianne

doi:10.1016/j.clml.2020.11.020

Cited by 8 publications

(3 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Twelve US studies and seven non-US studies reported on socioeconomic status and access to treatment (Supplementary Table 6 ), with mixed results. Lower socioeconomic status, whether defined by general socioeconomic status, household income, education level, or insurance status, was generally associated with worse access to treatment, including stem cell transplantation[ 27 , 36 , 37 , 39 , 40 , 43 , 50 , 54 , 58 , 72 , 80 , 88 , 93 , 97 ], although this was not a universal finding [ 36 , 42 , 43 , 47 , 50 , 54 , 58 , 60 , 66 , 96 ]. The effects of geography on access to treatment were reported in five US studies (Supplementary Table 7 ) and one study each in Canada and France [ 80 , 84 ].…”

Section: Resultsmentioning

confidence: 99%

“…Twenty-four US and 14 non-US studies reported on age and disparities in survival (Supplementary Table 8 ), and three US and 11 non-US studies on age and disparities in mortality (Supplementary Table 9 ). Most studies reported that survival and mortality worsened with increasing age [ 14 , 16 , 22 , 23 , 25 , 27 , 29 , 30 , 35 , 37 , 38 , 40 , 41 , 43 , 45 , 46 , 48 , 51 , 55 – 57 , 59 , 61 , 66 , 67 , 69 , 71 , 73 – 75 , 77 , 80 , 82 , 83 , 85 – 87 , 89 , 90 , 96 , 98 ].…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Global disparities in patients with multiple myeloma: a rapid evidence assessment

et al. 2023

View full text Add to dashboard Cite

There are disparities in outcomes for patients with multiple myeloma (MM). We evaluated the influence of sociodemographic factors on global disparities in outcomes for patients with MM. This rapid evidence assessment (PROSPERO, CRD42021248461) followed PRISMA-P guidelines and used the PICOS framework. PubMed and Embase® were searched for articles in English from 2011 to 2021. The title, abstract, and full text of articles were screened according to inclusion/exclusion criteria. The sociodemographic factors assessed were age, sex, race/ethnicity, socioeconomic status, and geographic location. Outcomes were diagnosis, access to treatment, and patient outcomes. Of 84 articles included, 48 were US-based. Worldwide, increasing age and low socioeconomic status were associated with worse patient outcomes. In the US, men typically had worse outcomes than women, although women had poorer access to treatment, as did Black, Asian, and Hispanic patients. No consistent disparities due to sex were seen outside the US, and for most factors and outcomes, no consistent disparities could be identified globally. Too few studies examined disparities in diagnosis to draw firm conclusions. This first systematic analysis of health disparities in patients with MM identified specific populations affected, highlighting a need for additional research focused on assessing patterns, trends, and underlying drivers of disparities in MM.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Global disparities in patients with multiple myeloma: a rapid evidence assessment

et al. 2023

View full text Add to dashboard Cite

show abstract

“…We observed a trend of younger age at diagnosis in our community, with a median age of 60 years and twothirds under 55 years 9 . Furthermore, in low-middle income countries (LMICs) like ours, there is a delay in the referral of patients, advanced stages at diagnosis, and limited access to novel drugs [9][10][11] . These limitations may influence poor outcomes in young MM patients in LMIC populations 12 .…”

Section: Introductionmentioning

confidence: 88%

Diagnosing and treating young multiple myeloma patients. Experience from a tertiary-care center in Mexico

Jaime‐Pérez¹,

Cruz²,

Tarín‐Arzaga³

et al. 2023

RMU

View full text Add to dashboard Cite

Background: Multiple myeloma (MM) is an infrequent hematologic entity in patients 40 years or younger, with a clinical presentation and disease course that differs from the older group. We report the clinical outcomes after diagnosing and treating young MM individuals from a hematologic referral center in a limited-resource context and briefly report the pertinent literature. Materials and methods: MM patients ≤ 40 years diagnosed and treated at a public hospital between 2008 and 2021were included, and their clinical features at diagnosis and during follow-up were recorded. Salient features, progression-free survival (PFS) and overall survival (OS) were compared with those of the older cohort. Results: We identified 8 (4.9%) MM patients ≤ 40 years at diagnosis. The most frequent initial clinical presentation was lower back pain and neurologic manifestations in the lower limbs; all presented with bony lesions. The extramedullary disease was identified in half; two patients met all CRAB criteria. There were no differences between young and older patients in median PFS (66 vs. 29.5 months, p = 0.331) and OS (77.8 vs. 55.1 months, p = 0.361). Median OS was similar among young and old patients who underwent autologous stem cell transplantation (77.8 vs. 79.1, p = 0.730). Conclusion: MM is rare in young patients; it predominates in males and has a torpid clinical course with high mortality. Early transplantation offers a reasonable opportunity for longer survival.

show abstract

Multiple myeloma in Latin America: A systematic review

de Moraes Hungria,

Peña,

Gómez‐Almaguer

et al. 2024

eJHaem

View full text Add to dashboard Cite

The incidence of multiple myeloma (MM) has surged globally, particularly in Latin American countries, and is attributable to an aging population and increased life expectancy. This systematic review analyzes the epidemiology, patient characteristics, and treatment outcomes for MM in selected Latin American countries: Brazil, Mexico, Colombia, Argentina, Chile, Peru, and Uruguay. PubMed and the Latin American and Caribbean Health Sciences Literature (LILACS), conference abstracts (between June 2019 and June 2022), and GLOBOCAN registry (January 2010 to June 2022) were electronically searched. Qualitative analysis employed the Joanna Briggs Institute's critical appraisal tool. Among the 586 screened articles, 26 met the inclusion criteria. The participants’ median age ranged from 54 to 67 years. GLOBOCAN data revealed that for MM, Brazil and Uruguay had the highest and lowest incidence, 5‐year prevalence, and mortality, respectively. Immunoglobulin G was the most common subtype detected. Stage III was frequently diagnosed. Though many approved drugs are available and bispecific antibodies hold promise as a future therapy, limited access, especially for CAR‐T cell‐based therapy remains a concern. The incidence of MM is increasing in Latin America. Resource constraints and costs hinder access to novel drugs and regimens. Understanding disease patterns and patient characteristics is vital to improve MM management in these countries.

show abstract

Impact of Socioeconomic Characteristics and Comorbidities on Therapy Initiation and Outcomes of Newly Diagnosed Multiple Myeloma: Real-World Data From a Resource-Constrained Setting

Cited by 8 publications

References 26 publications

Global disparities in patients with multiple myeloma: a rapid evidence assessment

Global disparities in patients with multiple myeloma: a rapid evidence assessment

Diagnosing and treating young multiple myeloma patients. Experience from a tertiary-care center in Mexico

Multiple myeloma in Latin America: A systematic review

Contact Info

Product

Resources

About